Moreover, FGFR4 deficiencies could regulate the TIICs and trigger a therapeutic immune response to tumors by the activation of the antigen presentation process and anti-cancer cellular immunity in NSCLC. Here, FGFR4 is linked to non-small cell lung carcinoma.